Skip to main content

Table 3 Baseline characteristics of subjects in the double-blind study

From: Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

VariableChloroquine groupPlacebo groupP value
Gender (F/M)44/1233/180.1108
Age55 ± 1255 ± 90.9999
Race (AA/NHW/H/NA)9/45/1/16/45/0/00.4990
Smoking status
 Current8100.4341
 Past21230.2962
Statin treatment15150.8310
Hypertension treatment20190.9999
Fish oil treatment5100.1632
Waist circumference110.4 ± 10.5108.9 ± 11.80.6538
BMI36.2 ± 5.034.2 ± 5.00.0433*
SBP
 Screen137.1 ± 14.3140.2 ± 13.20.2385
 Randomization129.2 ± 11.4134.0 ± 10.10.0237*
DBP
 Screen82.8 ± 9.583.0 ± 9.70.9483
 Randomization78.3 ± 7.479.7 ± 7.20.3244
Glucose5.48 ± 0.535.52 ± 0.640.6960
Triglycerides1.84 ± 1.041.82 ± 0.930.9155
HDL-C1.14 ± 0.261.14 ± 0.270.9603
Cholesterol5.00 ± 0.855.18 ± 1.150.3834
LDL-C3.04 ± 0.683.28 ± 0.820.1073
  1. Data represent mean ± SD